Coherus Biosciences Inc

Coherus Oncology, Inc. (Nasdaq: CHRS) is a commercial-stage oncology company focused on immuno-oncology therapies. Its approved product, LOQTORZI (toripalimab-tpzi), is a next-generation PD-1 inhibitor and the only FDA-approved treatment available in the U.S. for recurrent, locally advanced, or metastatic nasopharyngeal carcinoma, representing an estimated $250 million addressable market. The company's pipeline includes two mid-stage clinical candidates: casdozokitug, a first-in-class IL-27 antagonistic antibody in Phase 2 development for first-line hepatocellular carcinoma, and tagmokitug, a highly selective CCR8 Treg-depleting antibody in Phase 1b/2a studies across multiple solid tumor indications including head and neck squamous cell carcinoma, colorectal cancer, gastric and esophageal cancers. Coherus holds global rights to both pipeline candidates and pursues a strategy of growing LOQTORZI revenue while advancing combination regimens with its pipeline assets and exploring ex-U.S. licensing deals. The company completed its exit from its legacy biosimilar business in 2025 to focus exclusively on innovative oncology. Updated May 11, 2026